About this Research Topic
The field of immunological disease diagnosis has become increasingly critical due to the rise in immune-related health issues, such as autoimmune diseases, infectious diseases, fibrotic disorders, and cancer. These conditions are exacerbated by modern lifestyle changes and environmental factors, presenting significant challenges in treatment. The complexity of immune diseases necessitates a deep understanding of disease progression mechanisms, including key signaling pathways and immune cell interactions. While some critical targets have been identified, there remains a gap in the development of corresponding therapeutic drugs. Recent studies have highlighted the potential of advanced technologies, such as single-cell sequencing and proteo-transcriptomics, in accelerating drug discovery and development. However, there is still a need for comprehensive research to fully leverage these technologies in understanding and treating immune diseases.
This research topic aims to explore pharmacological mechanisms and drug development for immune diseases using advanced technologies. The focus is on analyzing immune disease-related signaling pathways, drug pharmacodynamics, and the development of therapeutic strategies. By employing cutting-edge techniques, the research seeks to answer key questions about the pathological mechanisms of immune diseases and improve the design of effective treatments. The goal is to deepen our understanding of these diseases and facilitate the discovery of novel therapeutic agents.
To gather further insights in the realm of advanced methods for immunological disease diagnosis, we welcome articles addressing, but not limited to, the following themes:
- New diagnostic and therapeutic approaches for immune diseases targeting key biomarkers or critical molecular targets.
- Mechanisms of drug action explored through proteomics and transcriptomics research.
- In-depth validation of disease targets beyond initial analysis, including signaling pathway and pharmacological analysis.
- Development of novel anti-inflammatory agents, including anti-infective and anti-fibrotic agents.
- Discovery of novel immuno-oncology drugs or adjuvant therapies for tumor immunotherapy.
- Discovery of novel agents targeting purinergic receptors for immunotherapy.
- Novel agents modulating cell-cell crosstalk for anti-inflammatory therapy.
Please note that manuscripts focusing on network pharmacology using docking and bioinformatic network analysis will be considered only if they provide specific experimental evidence for a single pathway or molecular target. Moreover, the structure-activity relationship (SAR) between the ligand and the target needs to be well characterized.
This research topic aims to explore pharmacological mechanisms and drug development for immune diseases using advanced technologies. The focus is on analyzing immune disease-related signaling pathways, drug pharmacodynamics, and the development of therapeutic strategies. By employing cutting-edge techniques, the research seeks to answer key questions about the pathological mechanisms of immune diseases and improve the design of effective treatments. The goal is to deepen our understanding of these diseases and facilitate the discovery of novel therapeutic agents.
To gather further insights in the realm of advanced methods for immunological disease diagnosis, we welcome articles addressing, but not limited to, the following themes:
- New diagnostic and therapeutic approaches for immune diseases targeting key biomarkers or critical molecular targets.
- Mechanisms of drug action explored through proteomics and transcriptomics research.
- In-depth validation of disease targets beyond initial analysis, including signaling pathway and pharmacological analysis.
- Development of novel anti-inflammatory agents, including anti-infective and anti-fibrotic agents.
- Discovery of novel immuno-oncology drugs or adjuvant therapies for tumor immunotherapy.
- Discovery of novel agents targeting purinergic receptors for immunotherapy.
- Novel agents modulating cell-cell crosstalk for anti-inflammatory therapy.
Please note that manuscripts focusing on network pharmacology using docking and bioinformatic network analysis will be considered only if they provide specific experimental evidence for a single pathway or molecular target. Moreover, the structure-activity relationship (SAR) between the ligand and the target needs to be well characterized.
Keywords: Advanced diagnostics, immunological disease, biomarkers, autoimmune diseases, infectious diseases, fibrotic diseases, cancer therapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
